{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:57:42Z","timestamp":1794477462157,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1038\/s41584-022-00798-0","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T11:03:14Z","timestamp":1656327794000},"page":"465-479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":597,"title":["Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4756-663X","authenticated-orcid":false,"given":"Laura C.","family":"Coates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Corp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Bertheussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Callis Duffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano B.","family":"Campanholo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3484-7977","authenticated-orcid":false,"given":"Jeffrey","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Fern\u00e1ndez-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6607-6070","authenticated-orcid":false,"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niti","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0600-4566","authenticated-orcid":false,"given":"Deepak R.","family":"Jadon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruvkumar","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Latella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8492-6342","authenticated-orcid":false,"given":"Ying-Ying","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6141-2824","authenticated-orcid":false,"given":"Christine","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-7916","authenticated-orcid":false,"given":"Luis Daniel","family":"Mazzuoccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Olsder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope Esther","family":"Palominos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Schick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Steinkoenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-6354","authenticated-orcid":false,"given":"Maarten","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"van der Windt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the GRAPPA Treatment Recommendations domain subcommittees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Campanholo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Helliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elaine","family":"Husni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhrukumar","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Daniel","family":"Mazzuoccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope Esther","family":"Palominos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"798_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin, C. T. et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis. 68, 1387\u20131394 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates, L. C. et al. Group for research and assessment of psoriasis and psoriatic arthritis: treatment recommendations for psoriatic arthritis 2015. Arthritis Rheumatol. 68, 1060\u20131071 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"798_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924\u2013926 (2008).","journal-title":"BMJ"},{"key":"798_CR4","first-page":"65","volume":"97","author":"LC Coates","year":"2021","unstructured":"Coates, L. C., Corp, N., van der Windt, D. A., Soriano, E. R. & Kavanaugh, A. GRAPPA treatment recommendations: an update from the 2020 GRAPPA annual meeting. J. Rheumatol. Suppl. 97, 65\u201366 (2021).","journal-title":"J. Rheumatol. Suppl."},{"key":"798_CR5","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins, J. P. T. et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).","journal-title":"BMJ"},{"key":"798_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3899\/jrheum.200126","volume":"96","author":"A Kavanaugh","year":"2020","unstructured":"Kavanaugh, A., Coates, L. C., van der Windt, D. A., Corp, N. & Soriano, E. R. GRAPPA treatment recommendations: updates and methods. J. Rheumatol. Suppl. 96, 41\u201345 (2020).","journal-title":"J. Rheumatol. Suppl."},{"key":"798_CR7","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3899\/jrheum.150614","volume":"43","author":"LC Coates","year":"2016","unstructured":"Coates, L. C. & Helliwell, P. S. Methotrexate efficacy in the tight control in psoriatic arthritis study. J. Rheumatol. 43, 356\u2013361 (2016).","journal-title":"J. Rheumatol."},{"key":"798_CR8","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease, P. J. et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 71, 1112\u20131124 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"798_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/annrheumdis-2019-216500","volume":"79","author":"E Vieira-Sousa","year":"2020","unstructured":"Vieira-Sousa, E. et al. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis. Ann. Rheum. Dis. 79, 490\u2013498 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR10","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","volume":"78","author":"LJJ van Mens","year":"2019","unstructured":"van Mens, L. J. J. et al. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. Ann. Rheum. Dis. 78, 610\u2013616 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","volume":"395","author":"IB McInnes","year":"2020","unstructured":"McInnes, I. B. et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 395, 1496\u20131505 (2020).","journal-title":"Lancet"},{"key":"798_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease, P. J. et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann. Rheum. Dis. 79, 123\u2013131 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes, I. B. et al. Trial of upadacitinib and adalimumab for psoriatic arthritis. N. Engl. J. Med. 384, 1227\u20131239 (2021).","journal-title":"N. Engl. J. Med."},{"key":"798_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo, E. G. et al. Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin. Arthritis Rheum. 48, 632\u2013637 (2019).","journal-title":"Semin. Arthritis Rheum."},{"key":"798_CR15","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 76, 1340\u20131347 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR16","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde, D. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394, 2108\u20132117 (2019).","journal-title":"Lancet"},{"key":"798_CR17","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde, D. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392, 2378\u20132387 (2018).","journal-title":"Lancet"},{"key":"798_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601","author":"A Deodhar","year":"2021","unstructured":"Deodhar, A. et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219601 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218808","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos, X. et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar, A. et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 71, 258\u2013270 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"798_CR21","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease, P. J. et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N. Engl. J. Med. 373, 1329\u20131339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"798_CR22","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3899\/jrheum.160275","volume":"43","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh, A. et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized Placebo-controlled FUTURE 2 study. J. Rheumatol. 43, 1713\u20131717 (2016).","journal-title":"J. Rheumatol."},{"key":"798_CR23","first-page":"890","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease, P. et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann. Rheum. Dis. 77, 890\u2013897 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","volume":"21","author":"DD Gladman","year":"2019","unstructured":"Gladman, D. D. et al. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res. Ther. 21, 38 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"798_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease, P. J., Helliwell, P. S., Hjuler, K. F., Raymond, K. & McInnes, I. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann. Rheum. Dis. 80, 185\u2013193 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease, P. J. et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1126\u20131136 (2020).","journal-title":"Lancet"},{"key":"798_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/annrheumdis-2021-eular.2678","volume":"80","author":"LE Kristensen","year":"2021","unstructured":"Kristensen, L. E. et al. Efficacy and safety of risankizumab in patients with active psoriatic arthritis after inadequate response or intolerance to DMARDs: 24-week results from the phase 3, randomised, double-blind, KEEPsAKE 1 trial. Ann. Rheum. Dis. 80, 1315\u20131316 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR28","first-page":"2027","volume":"72","author":"P Mease","year":"2021","unstructured":"Mease, P. et al. Efficacy and safety of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis in a randomised, double-blind, placebo-controlled, multiple-dose, phase 2b study. Arthritis Rheumatol. 72, 2027 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"798_CR29","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease, P. J. et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann. Rheum. Dis. 76, 1550\u20131558 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218870","author":"PJ Mease","year":"2020","unstructured":"Mease, P. J. et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218870 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR31","unstructured":"Orbai, A. et al. Efficacy of tofacitinib on dactylitis in individual digits in patients with active psoriatic arthritis. Arthritis Rheumatol. 72 [abstract] (2020)."},{"key":"798_CR32","unstructured":"Jadon, D. R. et al. Management of concomitant IBD or uveitis in patients with psoriatic arthritis: an updated review informing the 2021 GRAPPA treatment recommendations. J. Rheumatol. (In press)."},{"key":"798_CR33","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1080\/00365521.2018.1518482","volume":"53","author":"AM Ossum","year":"2018","unstructured":"Ossum, A. M. et al. Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study. Scand. J. Gastroenterol. 53, 1250\u20131256 (2018).","journal-title":"Scand. J. Gastroenterol."},{"key":"798_CR34","doi-asserted-by":"publisher","first-page":"e5652","DOI":"10.1097\/MD.0000000000005652","volume":"95","author":"M Landi","year":"2016","unstructured":"Landi, M. et al. Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine 95, e5652 (2016).","journal-title":"Medicine"},{"key":"798_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3109\/08820538.2016.1170161","volume":"32","author":"A Abbouda","year":"2017","unstructured":"Abbouda, A. et al. Psoriasis and psoriatic arthritis-related uveitis: different ophthalmological manifestations and ocular inflammation features. Semin. Ophthalmol. 32, 715\u2013720 (2017).","journal-title":"Semin. Ophthalmol."},{"key":"798_CR36","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s10067-014-2746-4","volume":"34","author":"S Donmez","year":"2015","unstructured":"Donmez, S., Pamuk, O. N., Akker, M. & Ak, R. Clinical features and types of articular involvement in patients with psoriatic arthritis. Clin. Rheumatol. 34, 1091\u20131096 (2015).","journal-title":"Clin. Rheumatol."},{"key":"798_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald, O. et al. Psoriatic arthritis. Nat. Rev. Dis. Prim. 7, 59 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"798_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24820","author":"H Chaudhary","year":"2021","unstructured":"Chaudhary, H. et al. All-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.24820 (2021).","journal-title":"Arthritis Care Res."},{"key":"798_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3899\/jrheum.170150","volume":"44","author":"A Ogdie","year":"2017","unstructured":"Ogdie, A. et al. Defining outcome measures for psoriatic arthritis: a report from the GRAPPA-OMERACT working group. J. Rheumatol. 44, 697\u2013700 (2017).","journal-title":"J. Rheumatol."},{"key":"798_CR40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3899\/jrheum.200127","volume":"96","author":"YY Leung","year":"2020","unstructured":"Leung, Y. Y. et al. The GRAPPA-OMERACT Working Group: 4 prioritized domains for completing the core outcome measurement set for psoriatic arthritis 2019 updates. J. Rheumatol. Suppl. 96, 46\u201349 (2020).","journal-title":"J. Rheumatol. Suppl."},{"key":"798_CR41","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates, L. C. et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386, 2489\u20132498 (2015).","journal-title":"Lancet"},{"key":"798_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","volume":"15","author":"JU Scher","year":"2019","unstructured":"Scher, J. U., Ogdie, A., Merola, J. F. & Ritchlin, C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat. Rev. Rheumatol. 15, 153\u2013166 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"798_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865","author":"ML Acosta Felquer","year":"2021","unstructured":"Acosta Felquer, M. L. et al. Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220865 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219961","author":"P Gisondi","year":"2021","unstructured":"Gisondi, P., Bellinato, F., Targher, G., Idolazzi, L. & Girolomoni, G. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219961 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"798_CR45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41584-019-0285-8","volume":"15","author":"A Bravo","year":"2019","unstructured":"Bravo, A. & Kavanaugh, A. Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. Nat. Rev. Rheumatol. 15, 645\u2013656 (2019).","journal-title":"Nat. Rev. Rheumatol."},{"key":"798_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.41191","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano, L. R. et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 72, 529\u2013556 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"798_CR47","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3899\/jrheum.161459","volume":"44","author":"W Tillett","year":"2017","unstructured":"Tillett, W. et al. A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. J. Rheumatol. 44, 1445\u20131452 (2017).","journal-title":"J. Rheumatol."},{"key":"798_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3899\/jrheum.111245","volume":"39","author":"WH Boehncke","year":"2012","unstructured":"Boehncke, W. H. Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting. J. Rheumatol. 39, 441\u2013444 (2012).","journal-title":"J. Rheumatol."},{"key":"798_CR49","unstructured":"Region, W. E. in Copenhagen: WHO Regional Office for Europe; 2021 https:\/\/www.who.int\/europe\/publications\/i\/item\/9789289057547 (2021)."}],"updated-by":[{"DOI":"10.1038\/s41584-022-00861-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00798-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00798-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00798-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:13:04Z","timestamp":1700752384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-022-00798-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1038\/s41584-022-00798-0","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"23 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the version of this article initially published, Spanish and Portuguese translations of the article were not available in the Supplementary Information and are now included in the online version of the article.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41584-022-00861-w","URL":"https:\/\/doi.org\/10.1038\/s41584-022-00861-w","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.C.C. has received grants\/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB. E.R.S. has participated in advisory boards, given conferences or received grants from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Glaxo, Janssen, Novartis, Pfizer, Sandoz, Roche and UCB. H.B. has received consultancy funding from Pfizer. K.C.D. has received research funding from Amgen, Abbvie, Celgene, Lilly, Novartis, Pfizer, Boehringer-Ingelheim, Stiefel, Janssen, UCB, and honoraria for consulting\/advising from Abbvie, Celgene, Lilly, Novartis, Pfizer, Boehringer-Ingelheim, Regeneron, Janssen, Ortho Dermatologic, UCB, Bristol-Myers Squibb, and Astra Zeneca. C.B.C. has received honoraria for consulting\/advising and fees for educational consulting from AbbVie, Bristol, Janssen, Lilly, Novartis, Pfizer, and UCB. L.E. has received educational\/research grants and consultation fees from Abbvie, Janssen, Novartis, UCB, Eli Lily, Sandoz and Pfizer. D.F.-A. declares that they have acted as a consultant of Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol, and received grant\/research support from Abbvie, UCB, Roche, Janssen, Pfizer, Amgen and Brystol. O.F. has received grant\/research support from AbbVie, Bristol-Myers Squibb, Eli Lilly, Novartis, Pfizer Inc and UCB; has received consulting fees from Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen and Pfizer Inc; and has been on speakers\u2019 bureaus for AbbVie, Janssen, Biogen and Pfizer Inc. A.G. is an adviser for AbbVie, Anaptys Bio, Boehringer Ingelheim, Bristol Myers Squibb, Incyte, InflaRx, Janssen, Novartis, Pfizer, UCB, and Viela Biosciences, and receives honoraria; A.G. receives research grants from AbbVie, UCB and National Psoriasis Foundation. D.D.G. has received grant support from Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, and received honoraria\/consulting fees from Abbvie, Amgen, BMS, Galapagos, Gilead, Eli Lilly, Janssen, Novartis, Pfizer and UCB. N.G. owns stock in UCB Pharma Ltd. P.S.H. received consultancy fees from Eli Lilly and fees for educational services from Pfizer, Novartis and Janssen. M.E.H. reports honoraria\/consulting fees from Abbvie, Amgen, BMS, Lilly, Novartis, Janssen, Pfizer and UCB. D.R.J. has received education and\/or research grants from AbbVie, Amgen, Biogen, BMS, Celgene, Celltrion Healthcare, Eli Lilly, Fresenius-Kabi, Galapagos, GSK, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB; D.R.J. has acted on advisory boards for AbbVie, Eli Lilly, Galapagos, GSK, Janssen, MSD, Novartis, Pfizer, Sandoz and UCB; D.R.J. has been a paid speaker for AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB. D.L. declares educational Honoraria for lectures from Abbvie, Leo Pharma and UCB Pharma. Y.-Y.L. has been paid as a speaker for AbbVie, DKSH, Janssen, Novartis and Pfizer. C.L. has Amgen stock and is employed by Aurinia Pharma US Inc. E.L. reports honoraria\/Consultant fees from Alfasigma, AbbVie, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer. L.D.M. has been a paid speaker for Abbvie, Elli Lilly, Novartis, Amgen, Janssen, UCB, Boehringer Ingelheim. P.J.M. declares research grants, consultation fees, and\/or speaker honoraria from Abbvie, Amgen, Bristol Myers, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Lilly, Merck, Novartis, Pfizer, SUN Pharma, and UCB. A.O. declares that she has consulted for Abbvie, Amgen, BMS, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB and has received grants from Abbvie, Novartis and Pfizer to University of Pennsylvania and Amgen to Forward databank; A.O.\u2019s spouse has received royalties from Novartis. P.E.P. declares honoraria\/research grants from AbbVie, Janssen, Novartis, Pfizer and UCB. M.d.W. declares that Stichting Tools has received fees for lectures or consultancy provided by M.d.W. from Celgene, Eli Lilly, Pfizer and UCB. A.K. has worked as a consultant to AbbVie, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Novartis, Pfizer and UCB. N.C., J.C., A.K., J.L., D.O\u2019S., W.O., L.S., I.S. and D.A.v.d.W. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}